Currently out of the existing stock ratings of David Novak, 18 are a BUY (90%), 2 are a HOLD (10%).

David Novak

Work Performance Price Targets & Ratings Chart

Analyst David Novak, carries an average stock price target met ratio of 71.11% that have a potential upside of 53.35% achieved within 296 days. Previously, David Novak worked at RAYMOND JAMES.

David Novak’s has documented 37 price targets and ratings displayed on 7 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ZYME, Zymeworks Common Stock at 11-Dec-2021.

Wall Street Analyst David Novak

Analyst best performing recommendations are on IMV (IMV).
The best stock recommendation documented was for IMV (IMV) at 7/16/2021. The price target of $20 was fulfilled within 10 days with a profit of $6.2 (44.93%) receiving and performance score of 44.93.

Average potential price target upside

of $276 (72.96%) on TCRT (ALAUNOS THERAPEUTICS).
of $13.2 (74.58%) on LPTX (LEAP THERAPEUTICS).
of $13.06 (81.54%) on ZYME (ZYMEWORKS COMMON STOCK).

CBIO Catalyst Biosciences ZYME Zymeworks Common Stock LPTX Leap Therapeutics TCRT Alaunos Therapeutics ZIOP ZIOPHARM Oncology MEDXF Medexus Pharmaceuticals IMV IMV

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Mitchell Kapoor (HC WAINWRIGHT)